We have observed
17 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after May 1, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
AN ANTIOXIDANT COMPOSITION
ANTIBODIES THAT BIND TO OX40 AND THEIR USES
COMPOSITIONS FOR THE TREATMENT OF FRAGILE X SYNDROME
NEW TALE-PROTEIN SCAFFOLDS AND USES THEREOF
SCREENING METHODS FOR IDENTIFYING PLASMODIUM PROTEASES INHIBITORS
De novo integron recombination sites and uses thereof
ANTI HER2 ANTIBODY FORMULATION
ANTIBODIES THAT BIND TO TL1A AND THEIR USES
EXPRESSION CONSTRUCTS AND METHODS FOR EXPRESSING POLYPEPTIDES IN EUKARYOTIC CELLS
PRODUCTION OF T CELL RETARGETING HETERO-DIMERIC IMMUNOGLOBULINS
EXPRESSION CONSTRUCTS AND METHODS FOR SELECTING HOST CELLS EXPRESSING POLYPEPTIDES
ANTIBODIES THAT BIND TO CCR6 AND THEIR USES
T CELL RETARGETING HETERO-DIMERIC IMMUNOGLOBULINS
CD3/CD38 T CELL RETARGETING HETERO-DIMERIC IMMUNOGLOBULINS AND METHODS OF THEIR PRODUCTION
ANTI-TRKA ANTIBODIES WITH ENHANCED INHIBITORY PROPERTIES AND DERIVATIVES THEREOF FOR USE IN TREATING BONE ASSOCIATED PAIN